Search

everythinglearnresearchcommunity

for

Search:↓

Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.

Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

New cytokine-targeted therapies show promise for treating alopecia areata.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Using a specific binding agent and low doses of FK506 can stimulate stem cells, speeding up skin healing by 25% and improving skin quality in rats and mice.

Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.

Some patients lost hair after taking interferon alpha 2B, but it improved for some while still on the treatment and for others after stopping it.

Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.

Intralesional vitamin D3 injections can improve vitamin D3 levels and may help treat alopecia areata.

Upadacitinib successfully treated a child's severe skin and hair loss issues.

Dupilumab for eczema may cause hair loss.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

A man developed facial skin lesions after a stem cell transplant, which improved with specific treatments.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

Apremilast improved symptoms in patients with severe skin conditions.

Denosumab, a bone loss treatment, may cause hair loss and skin reactions due to immune system effects.

Skin problems are common after stem cell transplants, and early treatment by dermatologists can improve patient outcomes.

Dupilumab can improve both atopic dermatitis and alopecia universalis.

Treatments for acute leukaemia lead to high remission rates, but relapses occur, requiring ongoing advancements in care.